PDS Biotechnology (PDSB) closed at $1.02 on November 11, 2026, down 1.0% from the previous close, on volume of 2,488,242 shares (30-day average 9,446,458).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Call Spread | 21-May-272.5 : 5 C | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
PDS Biotech Announces NantWorks Warrant Exercise Raising $3.9 Million
TipRanks (Tue, 10-Nov 8:34 AM ET)
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
Globe Newswire (Tue, 20-Oct 8:00 AM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Globe Newswire (Tue, 22-Sep 8:00 AM ET)
Globe Newswire (Mon, 14-Sep 10:30 AM ET)
Globe Newswire (Tue, 8-Sep 8:30 AM ET)
PDS Biotech Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 13-Aug 8:30 AM ET)
Market Chameleon (Wed, 15-Apr 7:09 AM ET)
Market Chameleon (Wed, 28-Jan 5:34 AM ET)
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
PDS Biotechnology trades on the NASDAQ stock market under the symbol PDSB.
As of November 12, 2026, PDSB stock price declined to $1.01 with 1,393,101 million shares trading.
PDSB has a beta of 3.89, meaning it tends to be more sensitive to market movements. PDSB has a correlation of 0.06 to the broad based SPY ETF.
PDSB has a market cap of $73.20 million. This is considered a Micro Cap stock.
In the last 3 years, PDSB traded as high as $6.85 and as low as $.20.
The top ETF exchange traded funds that PDSB belongs to (by Net Assets): VTI, VXF, IWC.
PDSB has underperformed the market in the last year with a price return of -4.7% while the SPY ETF gained +12.5%. However, in the short term, PDSB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +293.3% vs -1.0% return in SPY. But in the last 2 weeks, PDSB shares have been beat by the market, returning -33.6% compared to an SPY return of -1.5%.
PDSB support price is $.90 and resistance is $1.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PDSB shares will trade within this expected range on the day.
